

5. A method according to claim 1, wherein said cells are immune cells.
6. A method according to claim 1, wherein said cells are non-immune cells.
7. A method according to claim 1, wherein said cells express shared immunodominant cancer antigens.
8. A method according to claim 1, wherein said cells express shared not immunodominant cancer antigens.
9. A method according to claim 1, wherein said cells are Epstein-Barr virus-immortalized B-lymphoblastoid cell lines.
10. A method according to claim 1, wherein said cells are Pokeweed mitogen (PWM)-activated B-lymphocytes.
11. A method according to claim 1, wherein said cells are CD40 activated B-lymphocytes.
12. A method according to claim 1, wherein said cells are Phytohemagglutinin (PHA) + recombinant human interleukin-2 (rhIL-2)-activated PBMC.
13. A method according to claim 1, wherein said cells are Phytohemagglutinin (PHA) + recombinant human interleukin-2 (rhIL-2) + pokeweed mitogen (PWM)-activated PBMC.
14. A method according to claim 1, wherein said cells are dendritic cells, monocytes, macrophages.
15. A method according to claim 1, wherein said cells are CD34+ cells, fibroblasts, stem cells, fibroblasts and cheratinocytes.

Error! Reference source not found.

Serial No. unknown

16. A method according to claim 1, wherein histone deacetylase inhibitors are used in step d).

A²
17. A method according to claim 1, wherein said DNA hypomethylating agent is selected from 5-aza-cytidine or 5-aza-2'-deoxycytidine.

18. Cells obtainable by the method according to claim 1.

A³
23. Use according to claim 19, wherein said cells are stored as reservoir of pooled antigens.

A⁴
28. Vaccine according to claim 27, wherein the cells are used.

29. Vaccine according to claim 27, wherein cellular components are used.

A⁵
31. An article of manufacture comprising a vaccine according to claim 25 and a pharmaceutical composition suitable for systemic administration of a hypomethylating agent.